Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically engineered mice in drug development.

J N Livingston1

  • 1Bayer Corporation, West Haven, CT 06516-4175, USA.

Journal of Internal Medicine
|July 8, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway.

Diabetologia·1998
Same author

Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis.

Diabetes·1998
Same author

Role of the glucagon receptor COOH-terminal domain in glucagon-mediated signaling and receptor internalization.

Diabetes·1997
Same author

Insulin signaling in mice expressing reduced levels of Syp.

The Journal of biological chemistry·1996
Same author

Differential effects of acute hypertriglyceridemia on insulin action and insulin receptor autophosphorylation.

The American journal of physiology·1996
Same author

Glucagon.glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding.

The Journal of biological chemistry·1995
Same journal

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same journal

Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.

Journal of internal medicine·2026
Same journal

Multicenter validation of a severity index model for predicting postoperative acute kidney injury.

Journal of internal medicine·2026
Same journal

The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.

Journal of internal medicine·2026
Same journal

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same journal

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026
See all related articles

Transgenic animal models aid drug development for complex metabolic diseases like type 2 diabetes and obesity. These models evaluate molecular targets in physiological conditions, overcoming challenges posed by polygenic and non-genetic factors.

Area of Science:

  • Pharmacology and Endocrinology
  • Genetics and Molecular Biology

Background:

  • Complex metabolic diseases, including type 2 diabetes and obesity, pose significant challenges for pharmaceutical drug development.
  • The polygenic nature and influence of non-genetic factors complicate the identification of critical molecular targets.
  • Current therapeutic strategies face limitations in addressing these multifaceted conditions.

Purpose of the Study:

  • To explore the utility of transgenic animal models in understanding and developing therapies for type 2 diabetes and obesity.
  • To evaluate the advantages and limitations of using transgenic animals for drug development in metabolic diseases.
  • To provide an overview of recent transgenic study findings relevant to type 2 diabetes and obesity.

Main Methods:

  • Utilizing transgenic animal models to investigate metabolic and hormone signaling pathways.

Related Experiment Videos

  • Assessing molecular targets under physiological conditions within these models.
  • Reviewing existing literature and data from transgenic studies.

    • Main Results:

    • Transgenic models offer a physiological platform for evaluating drug targets.
    • These models help elucidate complex molecular processes in metabolic diseases.
    • Recent studies provide insights into potential therapeutic interventions.

    Conclusions:

    • Transgenic animal models are valuable tools in pharmaceutical research for metabolic diseases.
    • They facilitate the identification and validation of novel drug targets.
    • Further research using these models can accelerate the development of effective treatments for type 2 diabetes and obesity.